Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$1,243 Mln
Revenue (TTM)
$124 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.2 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
5.4
Industry P/E
--
EV/EBITDA
51.9
Div. Yield
0 %
Debt to Equity
0.2
Book Value
$2.8
EPS
$-0.5
Face value
--
Shares outstanding
80,015,667
CFO
$-224.86 Mln
EBITDA
$-357.23 Mln
Net Profit
$-356.00 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Monte Rosa Therapeutics Inc (GLUE)
| 9.5 | -3.3 | 9.5 | 270.0 | 30.1 | -- | -- |
|
BSE Sensex*
| -15.3 | -11.8 | -15.8 | -5.7 | 6.7 | 7.5 | 11.0 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Monte Rosa Therapeutics Inc (GLUE)
| 125.9 | 22.6 | -25.8 | -62.7 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Monte Rosa Therapeutics Inc (GLUE)
|
17.2 | 1,242.6 | 123.7 | -38.6 | -41.6 | -16.9 | -- | 5.4 |
| 62.9 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 66.6 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 44.0 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 91.2 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 65.4 | 7,360.8 | 1,396.6 | 316.9 | 59.8 | 153.6 | 24.3 | 153.4 | |
| 7.1 | 6,847.2 | 113.3 | -351.4 | -211.0 | 71.1 | -- | 0.0 | |
| 529.8 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 489.5 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 319.3 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The... company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd.; and Novartis. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts. Address: 321 Harrison Avenue, Boston, MA, United States, 02118 Read more
President, CEO & Director
Dr. Markus Warmuth M.D.
President, CEO & Director
Dr. Markus Warmuth M.D.
Headquarters
Boston, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Monte Rosa Therapeutics Inc (GLUE) is $17.17 (NASDAQ) as of 01-Apr-2026 16:14 EDT. Monte Rosa Therapeutics Inc (GLUE) has given a return of 30.14% in the last 3 years.
Since, TTM earnings of Monte Rosa Therapeutics Inc (GLUE) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-33.69
|
5.58
|
|
2024
|
-7.06
|
2.30
|
|
2023
|
-2.13
|
1.61
|
|
2022
|
-3.30
|
1.32
|
|
2021
|
-6.90
|
1.47
|
The 52-week high and low of Monte Rosa Therapeutics Inc (GLUE) are Rs 25.77 and Rs 3.50 as of 02-Apr-2026.
Monte Rosa Therapeutics Inc (GLUE) has a market capitalisation of $ 1,243 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Monte Rosa Therapeutics Inc (GLUE), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.72
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.